# Optimization and Investigation of Cruentaren A analogs

> **NIH NIH R01** · UNIVERSITY OF NOTRE DAME · 2021 · $352,952

## Abstract

Abstract
The development of new methods to treat cancer is greatly needed. In this application, we have identified a
macrocyclic small molecule that exhibits high differential selectivity for cancer cells vs. normal cells and aim to
develop more simplified analogs of this molecule in an effort to maximize efficiency as well as to decrease the
overall number of steps, which will likely lead to clinically useful molecules for the treatment of cancer. In addition,
we aim to interrogate the activity manifested by these compounds in both cellular and animal models of cancer,
with the goal of providing preclinical data to support the use of such compounds for translational development.

## Key facts

- **NIH application ID:** 10078544
- **Project number:** 5R01CA216919-05
- **Recipient organization:** UNIVERSITY OF NOTRE DAME
- **Principal Investigator:** Brian S J Blagg
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $352,952
- **Award type:** 5
- **Project period:** 2018-01-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10078544

## Citation

> US National Institutes of Health, RePORTER application 10078544, Optimization and Investigation of Cruentaren A analogs (5R01CA216919-05). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10078544. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*